MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
Br J Cancer. 2022 Sep;127(5):844-854. doi: 10.1038/s41416-022-01844-0. Epub 2022 May 26.
International Cancer Benchmarking Partnership Module 4 reports the first international comparison of ovarian cancer (OC) diagnosis routes and intervals (symptom onset to treatment start), which may inform previously reported variations in survival and stage.
Data were collated from 1110 newly diagnosed OC patients aged >40 surveyed between 2013 and 2015 across five countries (51-272 per jurisdiction), their primary-care physicians (PCPs) and cancer treatment specialists, supplement by treatment records or clinical databases. Diagnosis routes and time interval differences using quantile regression with reference to Denmark (largest survey response) were calculated.
There were no significant jurisdictional differences in the proportion diagnosed with symptoms on the Goff Symptom Index (53%; P = 0.179) or National Institute for Health and Care Excellence NG12 guidelines (62%; P = 0.946). Though the main diagnosis route consistently involved primary-care presentation (63-86%; P = 0.068), onward urgent referral rates varied significantly (29-79%; P < 0.001). In most jurisdictions, diagnostic intervals were generally shorter and other intervals, in particular, treatment longer compared to Denmark.
This study highlights key intervals in the diagnostic pathway where improvements could be made. It provides the opportunity to consider the systems and approaches across different jurisdictions that might allow for more timely ovarian cancer diagnosis and treatment.
国际癌症基准合作组织模块 4 报告了首次对卵巢癌(OC)诊断途径和间隔(症状出现至治疗开始)的国际比较,这可能有助于解释先前报告的生存率和分期差异。
从 2013 年至 2015 年在五个国家(每个司法管辖区 51-272 例)对 1110 例新诊断的 OC 患者进行了调查,收集了这些患者及其初级保健医生(PCP)和癌症治疗专家的数据,并通过治疗记录或临床数据库进行了补充。使用丹麦(调查回复最大的国家)作为参考,使用分位数回归计算了诊断途径和时间间隔的差异。
在 Goff 症状指数(53%;P=0.179)或国家卫生与保健卓越研究所 NG12 指南(62%;P=0.946)上诊断出症状的比例在司法管辖区之间没有显著差异。尽管主要的诊断途径始终涉及初级保健就诊(63-86%;P=0.068),但紧急转介率差异显著(29-79%;P<0.001)。在大多数司法管辖区,诊断间隔通常较短,而其他间隔,特别是治疗间隔,与丹麦相比更长。
本研究强调了诊断途径中可以改进的关键间隔。它为考虑不同司法管辖区的系统和方法提供了机会,这些方法可能有助于更及时地进行卵巢癌诊断和治疗。